Enveric Biosciences Reports New Brain Activity Data for Psychedelic-Derived Drug Candidate
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT ...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT ...
US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity ...
The next phase of psychedelic drug development may not involve psychedelics in the traditional sense. As researchers and pharmaceutical companies ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
